Otonomy Suspends Development of Lead Drug After Phase III Flop, Stock Plunges Post author:Sam Post published:August 29, 2017 Post category:BioPharma August 30, 2017By Alex Keown, BioSpace… Source: BioSpace You Might Also Like Pharma Execs are Attractive Candidates for Healthcare Leadership Roles March 22, 2018 Novartis Oncology Head to Retire for Personal Reasons December 14, 2017 Waters Corporation Q3 2017 Financial Results Webcast Invitation October 2, 2017
